New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:20 EDTALKS, SLXP, NPSP, MDVN, JAZZ, HSP, CBST, AUXL, AKRX, UTHRLeerink names top 10 acquisition candidates in biopharma
Leerink believes partnership and acquisition activity will remain a key feature of news flow and excess returns for investors in the biopharma industry during 2014 and into 2015. The firm's top 10 acquisition candidates in the space are: Alkermes (ALKS), Akorn (AKRX), Akorn (AUXL), Cubist (CBST), Hospira (HSP), Jazz Pharmaceuticals (JAZZ), Medivation (MDVN), NPS Pharmaceuticals (NPSP), Salix (SLXP) and United Therapeutics (UTHR).
Check below for free stories on ALKS;AKRX;AUXL;CBST;HSP;JAZZ;MDVN;NPSP;SLXP;UTHR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 7, 2014
16:37 EDTMDVNMedivation reports Q2 diluted EPS 60c, consensus 24c
Reports Q2 revenue $148.1M, consensus $125.62M.
16:16 EDTSLXPSalix sees FY14 EPS $3.16, consensus $6.53
Sees FY14 revenue approximately $1.6B, consensus $1.63B.
16:15 EDTSLXPSalix sees Q3 EPS $1.53, consensus $1.78
Subscribe for More Information
16:14 EDTSLXPSalix reports Q2 EPS $1.59, consensus $1.72
Subscribe for More Information
16:07 EDTMDVNMedivation trading halted, pending news
Subscribe for More Information
15:33 EDTSLXP, MDVN Notable companies reporting after market close
Subscribe for More Information
15:31 EDTMDVN, SLXPNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include CBS (CBS), consensus 72c; Consolidated Edison (ED), consensus 54c; Monster Beverage (MNST), consensus 75c; News Corporation (NWSA), consensus 3c; NVIDIA (NVDA), consensus 20c; Computer Sciences (CSC), consensus 94c; CareFusion (CFN), consensus 72c;DeVry Education (DV), consensus 67c; Salix Pharmaceuticals (SLXP), consensus $1.72; Federal Realty (FRT), consensus $1.21; SolarCity (SCTY), consensus (99c); Medivation (MDVN), consensus 24c; Sprouts Farmers Market (SFM), consensus 18c; Alnylam Pharmaceuticals (ALNY), consensus (56c); Lions Gate (LGF), consensus 17c; Mercadolibre (MELI), consensus 56c; Post Holdings (POST), consensus 27c; Assured Guaranty (AGO), consensus 35c; Great Plains Energy (GXP), consensus 41c; Air Lease (AL), consensus 52c; Ubiquiti Networks (UBNT), consensus 51c; SemGroup (SEMG), consensus 35c.
10:20 EDTAUXLHigh option volume stocks
Subscribe for More Information
08:10 EDTNPSPNPS Pharmaceuticals management to meet with Leerink
Subscribe for More Information
06:17 EDTAUXLAuxilium backs FY14 revenue guidance of $380M-$420M, consensus $397.45M
Subscribe for More Information
06:16 EDTAUXLAuxilium reports Q2 EPS (44c), consensus (21c)
Subscribe for More Information
August 6, 2014
16:51 EDTNPSPNPS Pharmaceuticals says on track to meet FY14 $100M-$110M revenue view
The company continues to expect FY14 operating expenses, excluding the impact of share-based compensation and cost of goods sold, to be between $180M-$200M.
16:48 EDTNPSPNPS Pharmaceuticals reports Q2 EPS 2c, consensus 0c
Reports Q2 revenue $56.1M, consensus $53.06M.
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTJAZZJazz Pharmaceuticals thesis remains intact, says Cowen
Subscribe for More Information
08:17 EDTCBSTCubist issues voluntary recall of certain lots of CUBICIN in the U.S.
Subscribe for More Information
06:51 EDTAKRXAkorn price target raised to $45 from $33 at Piper Jaffray
Piper Jaffray raised its price target for Akorn shares to $45 citing the company's "strong" Q2 results and attractive long-term growth story. Piper reiterates an Overweight rating on the stock.
06:33 EDTSLXPSalix upgraded to Buy from Hold at Cantor
Subscribe for More Information
06:23 EDTHSPMitsubishi UFJ to hold a conference
Subscribe for More Information
06:22 EDTCBSTJefferies to hold a summit
Boston Healthcare Summit to be held in Boston on August 6.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use